Abiraterone Acetate Tablet
Product Images NDC 68462-882

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Abiraterone Acetate (NDC 68462-882). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure.jpg (Structure)

Chemical structure of abiraterone acetate showing its molecular framework with rings, methyl groups, and heteroatoms depicted by standard chemical notation.*

FDA Label Image

Carton250mg

Packaging label for Abiraterone Acetate Tablets, USP 250 mg oral tablets by Glenmark Pharmaceuticals Inc., USA. The label shows the product name, strength (250 mg), quantity (120 tablets), storage instructions, and warnings. The product is identified with NDC 68462-135-08 and is labeled for prescription use only. The label also includes manufacturer information and contact details.*

FDA Label Image

Carton500mg

Packaging label for Abiraterone Acetate Tablets, USP 500 mg film-coated tablets by Glenmark Pharmaceuticals Inc., USA. The label displays the NDC 68462-882-60, indicates that the package contains 60 film-coated tablets, and includes storage instructions, manufacturing details (Product of Italy), and usage warnings. The label features a green and white color scheme with the Glenmark logo in red.*

FDA Label Image

Figure1.jpg (Figure1)

Kaplan-Meier overall survival curves from a clinical study comparing abiraterone acetate with placebo over a period of up to 21 months. The graph shows percent survival on the vertical axis and time to death in months on the horizontal axis, with separate curves for the abiraterone acetate and placebo groups.*

FDA Label Image

Figure2.jpg (Figure2)

A Kaplan Meier overall survival curve graph comparing survival over time in months from randomization between abiraterone acetate and placebo groups. The y-axis shows the percentage of subjects without death, while the x-axis measures months. The graph includes curves for both placebo and abiraterone acetate groups, with subject counts listed below the x-axis at different time points.*

FDA Label Image

Figure3.jpg (Figure3)

A Kaplan-Meier survival curve chart comparing the percentage of subjects without radiographic progression or death over months from randomization between Abiraterone acetate and placebo groups. The x-axis represents months from randomization, and the y-axis shows the percentage of subjects without radiographic progression or death. The graph includes the number of subjects at risk at various time points for both groups.*

FDA Label Image

Figure4

A survival curve chart comparing the percentage of subjects without death over months from randomization between abiraterone acetate and placebo groups. The chart includes lines for each group and a table below indicating the number of subjects at risk at various time points.*

FDA Label Image

Glenmarklogo

FDA Label Image

Logo.jpg (Logo)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.